Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?
Liver International · 2024-08 · 44 (8) · 1781-1796
DOI: 10.1111/liv.15938 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 16.04.2024. Verfasst von Guillaume Henin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-Gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium. Hauptthemen laut MEDLINE: Bariatric Surgery. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: This work was supported by a concerted research action grant "MyoMAFLD".
Abstract (Originalsprache)
Myosteatosis is highly prevalent in metabolic dysfunction‐associated steatotic liver disease (MASLD) and could reciprocally impact liver function. Decreasing muscle fat could be indirectly hepatoprotective in MASLD. We conducted a review to identify interventions reducing myosteatosis and their impact on liver function. Non‐pharmacological interventions included diet (caloric restriction or lipid enrichment), bariatric surgery and physical activity. Caloric restriction in humans achieving a mean weight loss of 3% only reduces muscle fat. Lipid‐enriched diet increases liver fat in human with no impact on muscle fat, except sphingomyelin‐enriched diet which reduces both lipid contents exclusively in pre‐clinical studies. Bariatric surgery, hybrid training (resistance exercise and electric stimulation) or whole‐body vibration in human decrease both liver and muscle fat. Physical activity impacts both phenotypes by reducing local and systemic inflammation, enhancing insulin sensitivity and modulating the expression of key mediators of the muscle‐liver‐adipose tissue axis. The combination of diet and physical activity acts synergistically in liver, muscle and white adipose tissue, and further decrease muscle and liver fat. Several pharmacological interventions (patchouli alcohol, KBP‐089, 2,4‐dinitrophenol methyl ether, adipoRon and atglistatin) and food supplementation (vitamin D or resveratrol) improve liver and muscle phenotypes in pre‐clinical studies by increasing fatty acid oxidation and anti‐inflammatory properties. These interventions are effective in reducing myosteatosis in MASLD while addressing the liver disease itself. This review supports that disturbances in inter‐organ crosstalk are key pathophysiological mechanisms involved in MASLD and myosteatosis pathogenesis. Focusing on the skeletal muscle might offer new therapeutic strategies to treat MASLD by modulating the interactions between liver and muscles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service d'Hépato-Gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
- Laboratory of Hepatogastroenterology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- Service d'Endocrinologie, Diabétologie et Nutrition, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
- Institute of Neuroscience, UCLouvain, Louvain-la-Neuve, Belgium.
ORCID-Profile: Guillaume Henin
Förderung
- This work was supported by a concerted research action grant "MyoMAFLD"
Zitieren
APA
Henin, G., Loumaye, A., Deldicque, L., Leclercq, I. A., & Lanthier, N. (2024). Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?. Liver International, 44(8), 1781-1796. https://doi.org/10.1111/liv.15938
Vancouver
Henin G, Loumaye A, Deldicque L, Leclercq IA, Lanthier N. Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?. Liver International. 2024;44(8):1781-1796. doi:10.1111/liv.15938
BibTeX
@article{Henin2024,
author = {Henin, Guillaume and Loumaye, Audrey and Deldicque, Louise and Leclercq, Isabelle A and Lanthier, Nicolas},
title = {Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction‐associated steatotic liver disease?},
journal = {Liver International},
year = {2024},
volume = {44},
number = {8},
pages = {1781--1796},
doi = {10.1111/liv.15938}
}
EUVIMED